The Latest Breaking News on Pharma

Pfizer (PFE) is grappling with financial difficulties and declining performance. Yet, with growing pharmaceutical demand and industry advancements, robust pharma stocks Zoetis (ZTS), Horizon Therapeutics (HZNP), and Novartis (NVS) appear as more promising buys this month. Read on.

The pharmaceutical industry is poised for sustained long-term growth due to increased investments in drug development and rapid technological advancements. While leading pharma stocks Pfizer (PFE) and Eli Lilly (LLY) stand to benefit, let us analyze which of these giants is poised for more gains this month. Keep reading.

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

Readers’ mail to The Hindu’s Letters to The Editor

“The announcement will finally pave the way for unfettered access to affordable generic versions of bedaquiline for all people”

After a large walkout forced at least a dozen stores to shut down in the Kansas City area, CVS promises change. But critics say the crisis in staffing and unfair pay extends beyond that market.

‘Vivek’s first business had a subsidiary in China’ which was closed ‘as the risks of doing business in China became apparent,’ Ramaswamy spokesperson says

While Palatin Technologies (PTN) has faced challenges with declining share price, negative analyst projections, and limited profitability, it's worth noting the consistent growth in the broader biotech industry. Thus, investors could find more stable returns in robust biotech stocks Protalix BioTherapeutics (PLX), Exelixis (EXEL), and Jazz Pharmaceuticals (JAZZ) instead. Read…

The growing adoption of innovative drugs and the heightened demand for personalized medicines are expected to boost the pharma industry. Therefore, it might be wise to buy fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), Novo Nordisk (NVO), and AstraZeneca PLC (AZN), which are rated an A (Strong Buy) in our…

“Based on strong scientific evidence, or because of lack of it, I have been critical of several of Himalaya Wellness’ products,” said doctor-influencer Cyriac Abby Philips aka The Liver Doc, whose X account was suspended today for posting “defamatory remarks” against the ayurvedic pharma company.

GSK-controlled company works on developing patient-administered treatment by end of the decade